Gene,Best SNP agreement across human cohorts,Potential for inhibition (+ indicates inhibition may improve response),Small molecular inhibitor available,Already a high priority immune target in solid tumors
CTSS,------,+-++,Yes,No
TREX1,----+-,+++-,First in 2021,Yes
DHFR,------,—+,Yes,Yes
ERAP1,++++++,–++,First in 2022,Yes
ERAP2,------,—-,First in 2022,Yes
GPLD1,+++++,+-++,MAB only,No
DYNLT1,------,++++,No,No
Tfh infiltrates,++++++,NA,N/A,Yes
PSMD11,--+-++,-+++,Yes,No
CTSW,-+-++-,—-,No,Yes
FAM216A,++-+++,–+-,No,No
LYZ,+--+++,++++,No,Yes
C3AR1,--+---,–++,Yes,Yes
DCTN5,++++++,—-,No,No
DBNDD1,+-+++-,+--+,No,No
FPR1,++++++,—+,Yes,Yes